A New Drug Effective on Human Ovarian and Prostate Cancer Cell Viability: Agomelatine

Published on Wednesday, 11 September 2019


Objective: Agomelatine is an antidepressant drug which recently started to be used in our country. Agomelatine is described as a potent agonist of melatonin receptor, which has an important physiological role especially in the regulation of human circadian rhythms. This study was conducted to investigate the effects of melatonin and agomelatine on human ovarian (A2780) and prostate (PC-3) cancer cell viability.

Materials and Methods: A2780 and PC-3 cell lines were used in the study. The 0.1 mM, 1 mM, 5 mM ve 10 mM concentrations of melatonin and agomelatine were administered to all cell lines for 24 h. Changes in cell viability were determined by the MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay. The 50% inhibitory concentration (LogIC50) was calculated according to MTT assay results.

Results: It was determined that all concentrations (0.1 mM, 1 mM, 5 mM ve 10 mM) of melatonin and agomelatine administered to human cancer cells (A2780 and PC-3) for 24 h reduced % cell viability (P<0.05).

Conclusion: The results of this study demonstrate that melatonin and agomelatine have strong cytotoxic and antitumor effects against human prostate and ovarian cancer cell lines.


NOTE: This publication cites (Ref. N.30): Di Bella G., Mascia F., Gualano L., Di Bella L. - Melatonin anticancer effect: review. Int J Mol Sci. 2013;14:2410–2430.


About this publication.

See also:

- Official Web Site: The Di Bella Method;

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- About Melatonin - In vitro, review and in vivo publications;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Neuroblastoma: Complete objective response to biological treatment;

- Oesophageal squamocellular carcinoma: a complete and objective response;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.